The present invention provides a novel human-derived monoclonal antibody specifically binding to human metapneumovirus F protein and neutralizing the human metapneumovirus, and an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising the antibody or an antigen-binding fragment thereof.